Single-cell Omics Market Size To Reach $4.64 Billion By 2030

Single-cell Omics Market Growth & Trends

The global single-cell omics market size is expected to reach USD 4.64 billion by 2030, expanding at 16.1% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing significance of single-cell omics in cell therapy, reproductive medicine, and personalized medicine are some of the key drivers for the market. In addition, increasing industry-academia collaborations are accelerating the adoption of single-cell omics technology in research & development. Similarly, supportive government legislation, rising funding for research, and various developments undertaken by market players are further contributing to the market expansion.

The rising demand for personalized medicine and growing adoption of omics-based tools to foster personalized medicine research are anticipated to cater to market demand throughout the forecast period. In addition, ongoing research efforts to explore the value of personalized medicine to develop targeted therapies tailored to the needs of individual patients have gained traction in past years. Thus, the evolution of precision medicine is pushing manufacturers to develop omics-based models for respective conditions. For instance, in January 2021 Mission Bio, Inc. launched Tapestri-a single cell multi-omics system for faster development of precision cancer therapies.

Single-cell-based omics have found a large range of applications in genetic engineering and cellular biology studies. This has allowed scientists to analyze cell lineage, identify cell types, and investigate cellular differentiation pathways, which has created huge traction for regenerative medicine and drug development processes. Thus, an emerging application of single-cell omics in the drug development process is anticipated to support the global market. For instance, in January 2021 Vizgen launched Pharma Accelerator Lab in response to the higher demand from top pharmaceutical companies who are incorporating single cellular & spatial transcriptomics solutions to bolster their drug development pipeline.

Furthermore, various organic and inorganic developments undertaken by participants, and increasing industry-academia collaborations have driven global market growth to a significant extent. For instance, in December 2022, 10x Genomics, Inc. announced the launch of its Xenium platform for in-situ analysis. In addition, in June 2022 Fluent BioSciences launched two novel products for 3 single cells RNA analyses. The newly launched T2 and T20 kits allowed scientists to immediately access the power of single-cell transcriptomics with relatively little capital investment.

 Request a free sample copy or view report summary: Single-cell Omics Market Report

Single-cell Omics Market Report Highlights

• By product type, the single-cell genomics segment dominated the market with a share of 45.8% in 2022, due to evolving demand from a wide range of end-users, potential clinical applications of single cells genomics platform, and technological advancements

• By application, the oncology segment dominated the industry with a share of 55.1% in 2022, due to the rising burden of cancer globally, rapid evolution in single cells analysis techniques, and rising adoption of omics-based tools to study cancer progression

• Based on end-user, academic, and research organizations segment dominated the market with a share of 42.8% in 2022. The high growth of the segment is attributed to the rising usage of technology on college campuses, increasing research efforts to develop novel modeling tools, and rising research studies by various research institutes to explore diverse applications of cell biology

• North America established a strong regional position in the global market with a 46.37% share in 2022 due to its highly developed healthcare infrastructure and favorable government policies

Single-cell Omics Market Segmentation

Grand View Research has segmented the global single-cell omics market based on product type, application, end-user, and region.

Single-cell Omics Product Type Outlook (Revenue, USD Million, 2018 - 2030)

• Single-Cell Genomics

• Single-Cell Transcriptomics

• Single-Cell Proteomics

• Single-Cell Metabolomics

Single-cell Omics Application Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

• Cell Biology

• Neurology

• Immunology

Single-cell Omics End-User Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical & Biotechnology Companies

• Academic and Research Organizations

• Hospital and Diagnostic Laboratories

• Others

Single-cell Omics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • The U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Single-cell Omics Market

• Danaher Corporation

• CYTENA GmbH

• 10x Genomics

• BD

• CELLENION

• PerkinElmer Inc.

• ANGLE plc

• Illumina, Inc.

• Bio-Rad Laboratories, Inc.

• Mission Bio

• Standard BioTools Inc.